The radioactive tracer market is projected to reach $54.29 billion by 2030, growing at a CAGR of 17.8% from 2022 to 2030. The market growth is attributed to the need for radioactive tracer post-thoracic surgery and the advantages of radioactive tracer over analog thoracic drainage devices. However, the lack of skilled personnel hinders market growth. Various initiatives, such as the European Union Committee's efforts to boost R&D activities in radioactive tracer and radioisotopes, are driving market growth. Key industry players include Rotem Industries Ltd, ABX advanced biochemical compounds GmbH, Invicro LLC, Cardinal Health Inc, and General Electric Co. Recent developments include Curium resuming the supply of molybdenum-99 (Mo-99) and technetium-99m (Tc-99m) generators to its customers and Telix Pharmaceuticals partnering with Invicro LLC to develop an artificial intelligence (AI) platform for Telix's PSMA-PET imaging agent.
Wed, 16 Aug 2023 12:32:50 GMT | GlobeNewswire